Increased risk of pneumonia among patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 108, Issue 2, 2013, Pages 240-248

  Long, Millie D ^a   Martin, Christopher ^a   Sandler, Robert S ^a   Kappelman, Michael D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MERCAPTOPURINE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG USE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NARCOTICS; ODDS RATIO; PATIENT SELECTION; PNEUMONIA; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873566314     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.406     Document Type: Article

References (37)

1. Hutfl ess SM, Weng X, LiüL et al. Mortality by medication use among patients with infl ammatory bowel disease, 1996-2003. Gastroenterology 2007; 133: 1779-86. (Pubitemid 350180814)
2. Ruhnke GW, Coca-Perraillon M, Kitch BT et al. Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993-2005. Med Care 2010; 48: 1111-6.
3. Huang SS, Johnson KM, Ray GT et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011; 29: 3398-412.
4. Colombel JF, Loft us EV Jr, Tremaine WJ et al. The safety profi le of infl iximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31. (Pubitemid 38040720)
5. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-34. (Pubitemid 43228641)
6. Coyne P, Hamilton J, Heycock C et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007; 34: 1832-6. (Pubitemid 350067642)
7. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
8. Lane MA, McDonald JR, Zeringue AL et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011; 90: 139-45.
9. Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factoralpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
10. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with infl ammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-40. (Pubitemid 44166594)
11. Long MD, Herfarth HH, Pipkin CA et al. Increased risk for non-melanoma skin cancer in patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.
12. Long MD, Porter CQ, Sandler RS et al. Suboptimal rates of cervical testing among women with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 549-53.
13. Stempel DA, Mauskopf J, McLaughlin T et al. Comparison of asthma costs in patients starting fl uticasone propionate compared to patients starting montelukast. Respir Med 2001; 95: 227-34. (Pubitemid 32624461)
14. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-90. (Pubitemid 44880029)
15. Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9. (Pubitemid 350181588)
16. Watkins RR, Lemonovich TL. Diagnosis and management of communityacquired pneumonia in adults. Am Fam Physician 2011; 83: 1299-306.
17. Carrie AG, Kozyrskyj AL. Disease, temporal and sociodemographic infl uences on initial treatment of community-acquired pneumonia in Manitoba, Canada. Int J Antimicrob Agents 2006; 28: 95-100. (Pubitemid 44108613)
18. Lund JL, Sturmer T, Porter CQ et al. Th iazolidinedione use and ulcerative colitis-related fl ares: An exploratory analysis of administrative data. Infl amm Bowel Dis 2011; 17: 787-94.
19. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defi ning comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9. (Pubitemid 41587600)
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
21. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fi brosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33: 55-60.
22. Seshasai SR, Kaptoge S, Th ompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specifi c death. N Engl J Med 2011; 364: 829-41.
23. Sands BE, Cuff ari C, Katz J et al. Guidelines for immunizations in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2004; 10: 677-92. (Pubitemid 39276481)
24. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with infl ammatory bowel diseases. J Crohns Colitis, advance online publication, 20 March 2012 (e-pub ahead of print).
25. Card T, Hubbard R, Logan RF. Mortality in infl ammatory bowel disease: A population-based cohort study. Gastroenterology 2003; 125: 1583-90. (Pubitemid 37500421)
26. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: Proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Th er 2010; 31: 1165-77.
27. Roy S, Ninkovic J, Banerjee S et al. Opioid drug abuse and modulation of immune function: Consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol 2011; 6: 442-65.
28. Dublin S, Walker RL, Jackson ML et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: A population-based case-control study. J Am Geriatr Soc 2011; 59: 1899-907.
29. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious s disease:?infections and mortality in association with therapies for Crohn ′ TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
30. Herrinton LJ, LiüL, Lafata JE et al. Estimation of the period prevalence of infl ammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Infl amm Bowel Dis 2007; 13: 451-61. (Pubitemid 46668251)
31. Aronsky D, Haug PJ, Lagor C et al. Accuracy of administrative data for identifying patients with pneumonia. Am J Med Qual 2005; 20: 319-28. (Pubitemid 41771782)
32. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303. (Pubitemid 43797117)
33. Almirall J, Gonzalez CA, Balanzo X et al. Proportion of communityacquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116 : 375-9. (Pubitemid 29382121)
34. Current cigarette smoking prevalence among working adults-United States, 2004-2010. MMWR Morb Mortal Wkly Rep 2011; 60: 1305-9.
35. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9.
36. Lewis JD, Gelfand JM, Troxel AB et al. Immunosuppressant medications and mortality in infl ammatory bowel disease. Am J Gastroenterol 2008; 103 : 1428-35; quiz 36. (Pubitemid 351813915)
37. Melmed GY, Agarwal N, Frenck RW et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with infl ammatory bowel disease. Am J Gastroenterol 105: 148-54.